Outcomes of a patient support programme for subcutaneous immunoglobulin therapy in patients with primary or secondary immunodeficiencies or chronic inflammatory demyelinating polyneuropathy

Background Subcutaneous immunoglobulin (SCIg) therapy is important in the treatment of primary (PID) and secondary immunodeficiencies (SID) and chronic inflammatory demyelinating polyneuropathy (CIDP). Patient support programmes (PSPs) help patients self‐administer medication regimens and play a mor...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Internal medicine journal 2024-11, Vol.54 (11), p.1827-1837
Hauptverfasser:	Crispin, Philip, Henderson, Robert, Yun, James, Crosbie, Christina, Tognarini, David, Youssef, Sherif, Barrese, Giulio, Fleischmann, Simone
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Child chronic inflammatory demyelinating polyneuropathy Demyelination Female Hizentra Hospitals Humans immunodeficiency Immunoglobulins Immunoglobulins - administration & dosage Immunoglobulins - therapeutic use Immunoglobulins, Intravenous - administration & dosage Immunoglobulins, Intravenous - therapeutic use Immunologic Deficiency Syndromes - drug therapy Immunologic Deficiency Syndromes - therapy Inflammation Infusions, Subcutaneous Injections, Subcutaneous Male Middle Aged Patient Education as Topic patient support programme Patients Polyneuropathy Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - drug therapy Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - therapy Retrospective Studies Self Administration subcutaneous immunoglobulin Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!